A Phase 1b trial of to evaluate the safety and tolerability of ORIC-114 in combination with SC amivantamab for the first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertion mutations
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs ORIC 114 (Primary) ; Amivantamab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a ORIC Pharmaceuticals media release, the company expects to initiate this trial in the first quarter of 2025 and to report initial data from the trial in mid-2026.